Allogene Therapeutics (ALLO) Total Liabilities (2019 - 2025)
Historic Total Liabilities for Allogene Therapeutics (ALLO) over the last 7 years, with Q3 2025 value amounting to $124.4 million.
- Allogene Therapeutics' Total Liabilities fell 74.18% to $124.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $124.4 million, marking a year-over-year decrease of 74.18%. This contributed to the annual value of $126.5 million for FY2024, which is 311.86% down from last year.
- According to the latest figures from Q3 2025, Allogene Therapeutics' Total Liabilities is $124.4 million, which was down 74.18% from $126.0 million recorded in Q2 2025.
- Over the past 5 years, Allogene Therapeutics' Total Liabilities peaked at $158.1 million during Q1 2023, and registered a low of $102.9 million during Q2 2021.
- Its 5-year average for Total Liabilities is $130.0 million, with a median of $126.0 million in 2025.
- As far as peak fluctuations go, Allogene Therapeutics' Total Liabilities skyrocketed by 4491.8% in 2022, and later plummeted by 2095.59% in 2024.
- Allogene Therapeutics' Total Liabilities (Quarter) stood at $125.6 million in 2021, then grew by 23.14% to $154.7 million in 2022, then fell by 15.57% to $130.6 million in 2023, then decreased by 3.12% to $126.5 million in 2024, then dropped by 1.65% to $124.4 million in 2025.
- Its Total Liabilities was $124.4 million in Q3 2025, compared to $126.0 million in Q2 2025 and $122.6 million in Q1 2025.